Renal

CROSS-DISEASE TRIALS:

**Localized**
- T1b or greater (has not spread beyond the kidney)
  - Clear Cell
    - No Prior Systemic Therapy
      - Nephrectomy Candidate
        - IRB# TBD
          - A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed By Nivolumab vs VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
        - IRB# TBD
          - EA8143: Phase 3 RandOMized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized RCC Undergoing Nephrectomy (PROSPER)
      - Prior Systemic Therapy
        - Track 2: Prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4
        - IRB# TBD
          - A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) + Pembro
    - IRB# TBD
      - S1500 – Cabozantinib, Crizotinib, Savolitinib and sunitinib
  - Non-Clear Cell
    - Papillary Renal Carcinoma
      - IRB# TBD
        - EA8143: Phase 3 RandOMized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized RCC Undergoing Nephrectomy (PROSPER)

http://www.ohsu.edu/research/rda/so/knight.php